Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Retained Earnings (2020 - 2025)

Historic Retained Earnings for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$610.8 million.

  • Foghorn Therapeutics' Retained Earnings fell 1338.46% to -$610.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$610.8 million, marking a year-over-year decrease of 1338.46%. This contributed to the annual value of -$558.2 million for FY2024, which is 1836.87% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Retained Earnings of -$610.8 million as of Q3 2025, which was down 1338.46% from -$595.0 million recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Retained Earnings peaked at -$185.9 million during Q1 2021, and registered a low of -$610.8 million during Q3 2025.
  • Its 5-year average for Retained Earnings is -$414.4 million, with a median of -$433.1 million in 2023.
  • Its Retained Earnings has fluctuated over the past 5 years, first plummeted by 6536.52% in 2021, then plummeted by 1338.46% in 2025.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Retained Earnings stood at -$264.3 million in 2021, then plummeted by 41.2% to -$373.1 million in 2022, then decreased by 26.38% to -$471.6 million in 2023, then decreased by 18.37% to -$558.2 million in 2024, then dropped by 9.43% to -$610.8 million in 2025.
  • Its Retained Earnings was -$610.8 million in Q3 2025, compared to -$595.0 million in Q2 2025 and -$577.0 million in Q1 2025.